NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

Part of paid clinical trials in Bryant, Arkansas.

Sponsor
Neurocrine Biosciences
Study ID
NCT07114874
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • NBI-1117568 — DRUG
    NBI-1117568 will be administered per schedule specified in the arm description.

Study Details

This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

Key Dates

Start date
Jul 11, 2025
Status verified
Apr 2026
Primary completion
Dec 31, 2031
Completion
Dec 31, 2031

Study Design

Enrollment
600 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: NBI-1117568
    Participants will receive NBI-1117568 once daily (QD) orally for up to 36 months.

Primary Outcome Measure

Number of Participants with Treatment-emergent Adverse Events [ Time Frame: Up to 36 months ]

Central Contacts

Locations (49)

FacilityCityStateZIPSite coordinators
Neurocrine Clinical SiteBryantArkansas72022-
Neurocrine Clinical SiteLittle RockArkansas72211-
Neurocrine Clinical SiteCerritosCalifornia90703-
Neurocrine Clinical SiteChinoCalifornia91710-
Neurocrine Clinical SiteCulver CityCalifornia90230-
Neurocrine Clinical SiteGarden GroveCalifornia92845-
Neurocrine Clinical SiteLa HabraCalifornia90631-
Neurocrine Clinical SiteLemon GroveCalifornia91945-
Neurocrine Clinical SiteOceansideCalifornia92056-
Neurocrine Clinical SitePico RiveraCalifornia90660-
Neurocrine Clinical SiteRiversideCalifornia92506-
Neurocrine Clinical SiteSan DiegoCalifornia92123-
Neurocrine Clinical SiteShermanCalifornia91403-
Neurocrine Clinical SiteTorranceCalifornia90504-
Neurocrine Clinical SiteWest HillsCalifornia91307-
Neurocrine Clinical SiteAtlantisFlorida30328-
Neurocrine Clinical SiteAventuraFlorida33108-
Neurocrine Clinical SiteDoralFlorida33178-
Neurocrine Clinical SiteHollywoodFlorida33024-
Neurocrine Clinical SiteMaitlandFlorida32751-
Neurocrine Clinical SiteMiamiFlorida33122-
Neurocrine Clinical SiteMiamiFlorida33155-
Neurocrine Clinical SiteMiami LakesFlorida33016-
Neurocrine Clinical SiteTampaFlorida33629-
Neurocrine Clinical SiteWest Palm BeachFlorida33407-
Neurocrine Clinical SiteAtlantaGeorgia30328-
Neurocrine Clinical SiteAtlantaGeorgia30331-
Neurocrine Clinical SiteDecaturGeorgia30030-
Neurocrine Clinical SitesPeachtree CornersGeorgia30071-
Neurocrine Clinical SiteChicagoIllinois60640-
Neurocrine Clinical SiteGaithersburgMaryland20877-
Neurocrine Clinical SiteBostonMassachusetts02116-
Neurocrine Clinical SiteWatertownMassachusetts02472-
Neurocrine Clinical SiteFlowoodMississippi39232-
Neurocrine Clinical SiteSt LouisMissouri63141-
Neurocrine Clinical SiteMarltonNew Jersey08053-
Neurocrine Clinical SiteCedarhurstNew York11516-
Neurocrine Clinical SiteNew YorkNew York10029-
Neurocrine Clinical SiteNew YorkNew York10036-
Neurocrine Clincial SiteStaten IslandNew York10314-
Neurocrine Clinical SitesThe BronxNew York10461-
Neurocrine Clinical SitesNorth CantonOhio44720-
Neurocrine Clinical SitePhiladelphiaPennsylvania19104-
Neurocrine Clinical SiteAustinTexas78754-
Neurocrine Clinical SiteDeSotoTexas75115-
Neurocrine Clinical SiteHoustonTexas77043-
Neurocrine Clinical SiteOremUtah84058-
Neurocrine Clinical SitesOremUtah84058-
Neurocrine Clinical SiteBellevueWashington98007-

Find similar trials in Bryant, AR

By condition
Schizophrenia
By specialty
PsychiatryMental healthBehavioral health
By research site
Neurocrine Clinical Site· Bryant, ARNeurocrine Clinical Site· Little Rock, ARNeurocrine Clinical Site· Cerritos, CANeurocrine Clinical Site· Chino, CANeurocrine Clinical Site· Culver City, CANeurocrine Clinical Site· Garden Grove, CA

Related Studies